miniDOX Chemotherapy for Advanced Gastric Cancer
the Cancer Therapy Advisor take:
For patients with advanced gastric cancer, chemotherapy can improve rates of overall survival. The combination of docetaxel, oxaliplatin, and capecitabine has shown to be a treatment regimen worth investigation.
Researchers sought to study this combination in patients with PS ECOG of 2 who were age 70 or older and had weight loss between 10% and 25%—these patients were defined as “suboptimal.” The researchers studied 43 patients with advanced gastric cancer who met “suboptimal” criteria who were previously untreated.
These patients received the “miniDOX” treatment regimen, which consisted of docetaxel 40 mg/m2 iv, day 1; oxaliplatin 80 mg/m2 iv, day 1; capecitabine 625 mg/m2 po bid, day 1 to day 21, every 21 days; after six courses, only capecitabine was maintained.
The primary endpoint of the study was response rate. Secondary study endpoints were overall survival, progression-free survival, and adverse events. Twelve patients has a PS ECOG of 2; 23 patients had weight loss between 10% and 25%; the median age of patients was 73.3 years (range 40-87; 28 patients were age 70 or older); 32 patients were male. Grade 3-4 adverse events included neutropenia (5 patients), febrile neutropenia (3 patients), pulmonary embolism (4 patients; 3 of which suffered sudden death), diarrhea (9 patients), paronychia (2 patients), ictus (1 patients), renal failure (1 patients, patient was diagnosed with infection/bacteriemia and died), hand-foot syndrome (4 patients), and asthenia (5 patients).
One patient experienced complete response, 23 patients experienced partial response (response rate: 56%). Three patients experienced disease progression. Median and 1-year progression-free survival was 5.5 months (18%) and overall survival was 13.3 months (52%).
The researchers concluded that toxicity associated with miniDOX was of concern but the treatment proved to be worthy of further research in patients with advanced gastric cancer who are classified as “suboptimal.”
For patients with advanced gastric cancer, chemotherapy can improve rates of overall survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer